UNSPSC 51412502: Chloracizine or chloracyzine

This classification denotes a vasodilating agent with the molecular formula C19H21ClN2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TZ913SWN6M, chemically known as 10h-phenothiazine, 2-chloro-10-(3-(diethylamino)-1-oxopropyl)- (9ci) but generally known as chloracizine, which bears US NIH Compound Identifier 13113. European Medicines Agency schedules Chloracyzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07464MIG.

The term CHLORACYZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Chloracizine or chloracyzine bears US NLM identifiers UMLS ID C0055327 and NCI Concept Code C80874. SMILES: CCN(CC)CCC(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.

UNSPSC 51412502 Chloracizine or chloracyzine is a Commodity code covering pharmaceutical active ingredients and finished medications used in emergency medical response and state health program management. State and local governments procure these products primarily through fire rescue departments, public health agencies, and cooperative purchasing alliances to stock emergency medication supplies and pharmacy benefit programs. The issuing bodies span city fire rescue departments, state health and human services commissions, and multistate cooperative purchasing organizations serving broad networks of participating jurisdictions. Scope of work includes sealed competitive bids for finished injectable medications (epinephrine, labetalol, diltiazem, adenosine) required by emergency medical services; requests for information to assess vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels; and RFPs for generic multi-source pharmaceutical products distributed through authorized wholesalers to state and local health facilities.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted an IFB (26P00188) on April 24, 2026, due April 8, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with four injectable medication line items totaling approximately $40,000 under a one-year term with renewal options, including a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploration of alternative contracting models outside conventional PBM and GPO relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to distribute across participating state and local facilities in Minnesota and Oregon, requiring manufacturers to supply through three authorized wholesalers with NDC-specific product information, cGMP and DSCSA compliance certification, and a two-year contract term. MMCAP evaluates proposals weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent on administrative and EDI compliance, with a 3 percent administrative fee on all purchases.